# Vonafexor ALPort Syndrome Efficacy & Safety TRIAl-1 (ALPESTRIA-1)

> **NCT06425055** · PHASE2 · COMPLETED · sponsor: **Enyo Pharma** · enrollment: 26 (actual)

## Conditions studied

- Alport Syndrome

## Interventions

- **DRUG:** Vonafexor

## Key facts

- **NCT ID:** NCT06425055
- **Lead sponsor:** Enyo Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-08-01
- **Primary completion:** 2025-09-04
- **Final completion:** 2025-11-20
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2026-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06425055

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06425055, "Vonafexor ALPort Syndrome Efficacy & Safety TRIAl-1 (ALPESTRIA-1)". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT06425055. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*